Effect of Aromatase Inhibitor Therapy on Blood Vessel Function in Postmenopausal Women With Breast Cancer

• Status: Active, not recruiting
• Trial end date: 2021-09-30
• Target enrollment: 0
• Participant gender: Female

Summary

RATIONALE: Aromatase inhibitor therapy is used in treating postmenopausal women who have hormone-dependent breast cancer. It is not yet known what effect aromatase inhibitor therapy has on blood vessel function.

PURPOSE: This clinical trial is studying the effect of aromatase inhibitor therapy on blood vessel function in postmenopausal women with breast cancer.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mayo Clinic
• Collaborator: National Cancer Institute (NCI)
• Treatments: Anastrozole; Aromatase Inhibitors; Exemestane; Letrozole

Criteria

DISEASE CHARACTERISTICS:

• Diagnosis of breast cancer

• Ductal carcinoma in situ (DCIS) allowed provided the patient will not receive tamoxifen as part of treatment for their cancer

• May not have had a prior mastectomy with requirement for mastectomy of the contralateral breast

• No requirement for axillary lymph node dissection with a history of contralateral mastectomy and/or contralateral axillary lymph node dissection

• Hormone receptor status meeting 1 of the following criteria:

• Hormone receptor negative and not eligible for aromatase inhibitor therapy (AI)

• Hormone receptor positive and are not receiving an AI

PATIENT CHARACTERISTICS:

• Postmenopausal

• No known or symptomatic coronary artery disease

• No significant co-morbidities, including any of the following conditions:

• Active renal or hepatic disease

• Known uncontrolled and/or untreated peripheral arterial disease

• Uncontrolled and/or untreated hypertension

• Uncontrolled and/or untreated diabetes

• Uncontrolled and/or untreated hyperlipidemia

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics

• More than 7 days since prior hormone replacement therapy or hormone-based contraception

• More than 12 months since prior and no concurrent tamoxifen or aromatase inhibitor therapy for this disease

• More than 12 months since prior and no concurrent chemotherapy for this disease

• No prior bilateral mastectomy